DK2914302T3 - Radioaktivt markeret antistof samt anvendelser af det - Google Patents
Radioaktivt markeret antistof samt anvendelser af det Download PDFInfo
- Publication number
- DK2914302T3 DK2914302T3 DK13788728.7T DK13788728T DK2914302T3 DK 2914302 T3 DK2914302 T3 DK 2914302T3 DK 13788728 T DK13788728 T DK 13788728T DK 2914302 T3 DK2914302 T3 DK 2914302T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- sequence
- region
- radioactive
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Radioaktivt konjugat omfattende et antistof specifikt for CD38 omfattende en HCDR1-region af sekvensen GFTFSSYYMN (SEQ ID NO: 1) eller SYYMN (SEQ ID NO: 14), en IICDR2-region af sekvensen GISGDPSNTYYADSVKG (SEQ ID NO: 2), en HCDR3 af sekvensen DLPLVYTGFAY (SEQ ID NO: 3), en LCDR1-region af sekvensen SGDNLRHYYVY (SEQ ID NO: 4), en LCDR2-region af sekvensen GDSKRPS (SEQ ID NO: 5) og en LCDR3-region af sekvensen QTYTG-GASL (SEQ ID NO: 6).
2. Radioaktivt konjugat ifølge krav 1, hvor HCDR1-regionen omfatter SYYMN (SEQ ID NO: 14).
3. Radioaktivt konjugat ifølge kravl, hvor den radioaktive nukleid omfatter en a-partikel-emitterende isotop.
4. Radioaktivt konjugat ifølge krav 1, hvor nukleiden, der er radioaktiv, er valgt blandt: jod-131, yttrium-90, lutetium-177, kobber-67, astat-211, bismuth-212, bis-muth-213 og actinium-225.
5. Radioaktivt konjugat ifølge krav 4, hvor nukleiden, der er radioaktiv, er bismuth-213.
6. Radioaktivt konjugat ifølge krav 1, 2, 3, 4 eller 5, hvor antistoffet omfatter en variabel tung kæde med sekvensen: QVQLVEStXKJt-VQKKkSLRlxSC'AASGFrb’SSYYMNWVRQAPtJKClIIiWVSfilSGDPSN’ITY .^DSVKORKriSRDNSKNTLYt.QMNSIJiABDTAVTYCARDIPLVVTGFAYWGQGTLVTVSS (SKQiDNO: 10) og en variabel let kæde med sekvensen: DlHtY'QPPSVSVArcQTARISCSGDNLRilYYVYWYQQKPGQAPVLVIYGDSKRPSClFERFS GSNSGNTATt;riSG1[X)AEDiiAi>YYOQTYTGGASLVreGGTKLTVl.GQ (SEQ ID NO: 11).
7. Radioaktivt konjugat ifølge krav 1, 2, 3, 4, 5 eller 6, hvor antistoffet omfatter en modificeret lgGl-Fe-region, hvor modifikationen forøger ADCC- eller CDC-aktiviteten.
8. Radioaktivt konjugat ifølge krav 1, 2, 3, 4, 5, 6 eller 7 til anvendelse til behandling af multipel myelom i et individ, som behøver det.
9. Radioaktivt konjugat til anvendelse ifølge krav 8, hvor det radioaktive konjugat omfatter et for CD38 specifikt antistof, der omfatter en HCDR1-region af sekvensen GFTFSSYYMN (SEQ ID NO: 1) eller af sekvensen SYYMN (SEQ ID NO: 14), en HCDR2-region af sekvensen GISGDPSNTYYADSVKG (SEQ ID NO: 2), en HCDR3-region af sekvensen DLPLVYTGFAY (SEQ ID NO: 3), en LCDR1-region af sekvensen SGDNLRHYYVY (SEQ ID NO: 4), en LCDR2-region af sekvensen GDSKRPS (SEQ ID NO: 5) samt en LCDR3-region af sekvensen QTYTGGASL (SEQ ID NO: 6) og213Bi.
10. Radioaktivt konjugat til anvendelse ifølge krav 9, hvor HCDR1-regionen af det radioaktive konjugat omfatter SYYMN (SEQ ID NO: 14).
11. Radioaktivt konjugat til anvendelse ifølge krav 9, hvor det radioaktive konjugat omfatter en antistof-region, der omfatter en variabel tung kæde med sekvensen: QVQLVBSCKXhNQPCK:Si,ROSCAASGFrrøSYYMNWVRQAKii<OLBWVS<;iSGl>PSNliYY ADSyKGRFriSRDNNKNTLYLQMNSLRAEDTAVYYCARDLPJATTGPAYWOQGYLVTVSS (SEQ ID NO: ΙΟ.ί og en variabel let kæde med sekvensen: DIHi.TQPPSVSVAK.TQTARTSCSGDNLSH'YYVYWYQQKPCjQAPVLViyGDSKRPSOIRBRFS OSN$GNTA'rLTiSOTQAEDEAi>YY<XJ’rYTOOASLVlKKIOTKIA'ViX)Q (SEQ II> NO: i I}.
12. Radioaktivt konjugat ifølge et hvilket som helst af de forudgående krav til anvendelse til behandling af ikke-Hodgkin-lymphom i et individ, der behøver det.
13. Radioaktivt konjugat til anvendelse ifølge krav 12, hvor det radioaktive konjugat omfatter et for CD38 specifikt antistof omfattende en HCDR1 -region af sekvensen GFTFSSYYMN (SEQ ID NO: 1) eller af sekvensen SYYMN (SEQ ID NO: 14), en HCDR2-region af sekvensen GISGDPSNTYYADSVKG (SEQ ID NO: 2), en HCDR3-region af sekvensen DLPLVYTGFAY (SEQ ID NO: 3), en LCDRl-region af sekvensen SGDNLRHYYVY (SEQ ID NO: 4), en LCDR2-region af sekvensen GDSKRPS (SEQ ID NO: 5) samt en LCDR3-region af sekvensen QTYTGGASL (SEQ ID NO: 6) og 213Bi.
14. Radioaktivt konjugat til anvendelse ifølge krav 13, hvor det radioaktive konjugats HCDR1-region omfatter SYYMN (SEQ ID NO: 14).
15. Radioaktivt konjugat til anvendelse ifølge krav 13, hvor det radioaktive konjugat omfatter et for CD38 specifikt antistof omfattende en HCDR1-region af sekvensen GFTFSSYYMN (SEQ ID NO: 1) eller af sekvensen SYYMN (SEQ ID NO: 14), en HCDR2-region af sekvensen GISGDPSNTYYADSVKG (SEQ ID NO: 2), en HCDR3-region af sekvensen DLPLVYTGFAY (SEQ ID NO: 3), en LCDRl-region af sekvensen SGDNLRHYYVY (SEQ ID NO: 4), en LCDR2-region af sekvensen GDSKRPS (SEQ ID NO: 5) samt en LCDR3-region af sekvensen QTYTGGASL (SEQ ID NO: 6) og 213Bi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722256P | 2012-11-05 | 2012-11-05 | |
| PCT/EP2013/072944 WO2014068114A1 (en) | 2012-11-05 | 2013-11-04 | Radiolabelled antibody and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2914302T3 true DK2914302T3 (da) | 2017-04-10 |
Family
ID=49552350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13788728.7T DK2914302T3 (da) | 2012-11-05 | 2013-11-04 | Radioaktivt markeret antistof samt anvendelser af det |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9486547B2 (da) |
| EP (1) | EP2914302B1 (da) |
| DK (1) | DK2914302T3 (da) |
| ES (1) | ES2621377T3 (da) |
| WO (1) | WO2014068114A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2860192T3 (pl) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| HRP20240338T1 (hr) * | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3535295A1 (en) | 2016-11-02 | 2019-09-11 | EngMab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| JP7370958B2 (ja) * | 2017-07-31 | 2023-10-30 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 血液悪性腫瘍の治療 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| IL317328A (en) * | 2018-12-14 | 2025-01-01 | Morphosys Ag | Antibody formulations |
| AU2022262350B2 (en) | 2021-04-20 | 2026-05-07 | Terrapower Isotopes, Llc | Titania based generators for ac-225 generation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| ES2541436T3 (es) | 2004-02-06 | 2015-07-20 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| PL2860192T3 (pl) | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| NZ607473A (en) | 2010-09-27 | 2014-11-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
-
2013
- 2013-11-04 DK DK13788728.7T patent/DK2914302T3/da active
- 2013-11-04 WO PCT/EP2013/072944 patent/WO2014068114A1/en not_active Ceased
- 2013-11-04 ES ES13788728.7T patent/ES2621377T3/es active Active
- 2013-11-04 US US14/438,882 patent/US9486547B2/en active Active
- 2013-11-04 EP EP13788728.7A patent/EP2914302B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2914302B1 (en) | 2017-01-04 |
| US20150283275A1 (en) | 2015-10-08 |
| EP2914302A1 (en) | 2015-09-09 |
| US9486547B2 (en) | 2016-11-08 |
| ES2621377T3 (es) | 2017-07-03 |
| WO2014068114A1 (en) | 2014-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2914302B1 (en) | Radiolabelled antibody and uses thereof | |
| KR101893720B1 (ko) | 방사 면역 접합체 및 그 용도 | |
| US11970542B2 (en) | Bispecific antibodies specific for treating hematological malignancies | |
| JP6590985B2 (ja) | 抗原発現を上方制御するための方法 | |
| JP2024016055A (ja) | 血液悪性腫瘍の治療 | |
| US20250319216A1 (en) | Radiopharmceutical complexes targeting prostate-specific membrane antigen and its combinations | |
| JP2018530993A6 (ja) | シンデカン−１に特異的なヒト化モノクローナル抗体 | |
| WO2024173876A1 (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| Rousseau et al. | Radiolabeled Antibodies for Cancer Radioimmunotherapy | |
| US20150071853A1 (en) | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof | |
| Puchol Tarazona et al. | Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer | |
| EP1091757B1 (en) | Alpha emitting constructs and uses thereof | |
| EP4298126A1 (en) | Antibodies to igf2r and methods | |
| EP2193147B1 (en) | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof | |
| KR20260022886A (ko) | 방사성동위원소 표지된 cd25 표적 항체를 유효성분으로 포함하는 암의 방사면역치료용 약제학적 조성물 | |
| CN101454346A (zh) | 用于乳腺癌和卵巢癌诊断和治疗的癌性疾病调节抗体 | |
| WO2026050866A1 (en) | Methods of treating cancer with combination therapy comprising anti-nectin-4 radioimmunoconjugate and pd-1/pd-l1 inhibitors | |
| WO2025230920A2 (en) | Radioimmunotherapy for treatment of acute myeloid leukemia | |
| WO2025242909A1 (en) | CD30-targeting antibody-radioligand conjugates and their therapeutic use | |
| Yakushijin et al. | Concurrent Administration of Rituximab and CHOP Chemotherapeutic Agents for Outpatients with CD20-positive Lymphoma |